Stoke Therapeutics, Inc.
STOK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,377,374 | $662,316 | $384,787 | $629,033 |
| - Cash | $83,394 | $101,472 | $274,817 | $127,983 |
| + Debt | $0 | $2,296 | $2,351 | $2,322 |
| Enterprise Value | $1,293,980 | $563,140 | $112,321 | $503,372 |
| Revenue | $10,632 | $13,817 | $158,569 | $22,614 |
| % Growth | -23.1% | -91.3% | 601.2% | – |
| Gross Profit | $9,643 | $13,817 | $158,569 | $22,614 |
| % Margin | 90.7% | 100% | 100% | 100% |
| EBITDA | -$38,633 | -$26,854 | $111,717 | -$13,127 |
| % Margin | -363.4% | -194.4% | 70.5% | -58% |
| Net Income | -$38,347 | -$23,483 | $112,879 | -$10,482 |
| % Margin | -360.7% | -170% | 71.2% | -46.4% |
| EPS Diluted | -0.65 | -0.4 | 1.9 | -0.18 |
| % Growth | -62.5% | -121.1% | 1,155.6% | – |
| Operating Cash Flow | -$30,366 | -$25,422 | $131,827 | -$23,193 |
| Capital Expenditures | -$132 | -$154 | -$152 | -$42 |
| Free Cash Flow | -$30,498 | -$25,576 | $131,675 | -$23,235 |